Narrative-first, evidence-driven

Back to case studies [pdf]

Receipts: tracked in Methods and Sources by type: Primary documents | Official data | Independent analysis

Pattern summary

This is not a “pharma is evil” story. Innovation is real. So are the ways an essential market can be rigged when rules meant to protect safety or reward invention are easy to turn into moats.

The repeating pattern is simple:

• competition gets blocked right when it might lower prices
• the real price stays hidden behind contracts and rebates
• middlemen get paid more when list prices go up
• enforcement arrives years after patients have already paid, rationed, or gone without

That is why this case belongs in the monthly squeeze. Medicines are not optional for the people who need them. When the system is designed so the safest move is also the most expensive one, families lose money, time, trust, and sometimes health.

What this looks like in human terms

A parent gets to the pharmacy counter and learns the refill costs far more than expected. The list price is brutal. The insurance price is different. A coupon helps sometimes, but not always. The plan says the drug is covered, but not before another round of paperwork. The pharmacist cannot explain where the money is going because the contract chain is hidden from them too.

That does not require a cartoon villain. It only requires a market where patients cannot walk away, competitors cannot enter on time, and the people in the middle do better when the sticker price climbs.

Mode 1: Entry blocking when competition should arrive

What it is: A manufacturer uses distribution controls, supplier contracts, patent settlements, or regulatory pathways to keep generic or biosimilar competitors from entering the market when entry would cut prices.

Examples:

• Vyera used a voluntary restricted distribution setup, supplier exclusivity, and data-blocking agreements to make Daraprim sample access and generic development harder. [confirmed]
• Mylan’s EpiPen strategy included school-discount arrangements that pushed out rivals and a patent settlement that delayed Teva’s generic launch. [confirmed]
• URL Pharma used the FDA’s Unapproved Drugs Initiative to secure exclusivity for colchicine and wipe older competitors off the market before later competition arrived. [confirmed]

Missing guardrail: Safety and exclusivity rules still do not reliably distinguish between real protection and moat-building. Partial fixes exist, but they arrived late and still leave room for pay-for-delay and distribution games.

Mode 2: The real price stays hidden

What it is: The list price is public theater. The real money moves through rebates, fees, and side payments that patients, employers, and often regulators cannot see clearly in time to correct.

Examples:

• The Senate Finance insulin investigation found rebate shares climbing from low single digits to more than half of list price over time. [confirmed]
• Mylan disclosed in congressional testimony that EpiPen’s list price and its net revenue per two-pack were wildly different. [confirmed]
• Employers and patients still rarely see a clean picture of list price, net price, retained rebates, and fees in one place. [confirmed/plausible]

Missing guardrail: There is still no durable public rule requiring usable net-price disclosure across manufacturers and PBMs, and no easy way for ordinary buyers to see who kept which slice.

Mode 3: The middleman’s cut rewards the wrong thing

What it is: PBMs are supposed to manage costs, but percentage-of-list-price fees, rebate structures, and formulary leverage can reward higher list prices instead of lower patient cost.

Examples:

• Senate investigators found PBM fee structures tied to wholesale acquisition cost and price-protection clauses that made higher list prices profitable for everyone except the patient. [confirmed]
• PBMs used formulary leverage to pressure insulin makers for larger rebates, and manufacturers responded by building those rebates into still-higher list prices. [confirmed]
• Patients in high-deductible plans and uninsured patients were often exposed to the inflated front-end price while the back-end deal stayed hidden. [confirmed]

Missing guardrail: Commercial markets still lack clean bans on list-price-based PBM compensation, broad point-of-sale rebate pass-through, and consistent anti-spread-pricing rules.

Mode 4: Buy it, spike it

What it is: A company acquires an old or low-competition drug, adds little or no new value, and raises the price because patients do not have a real substitute.

Examples:

• Daraprim’s price jumped from $13.50 to $750 per pill after acquisition. [confirmed]
• Valeant sharply raised Nitropress and Isuprel prices after acquisition, apparently to extract value before generic pressure closed the window. [confirmed]
• Colchicine became dramatically more expensive after exclusivity kicked in, even though the medicine itself had existed for centuries. [confirmed]

Missing guardrail: U.S. law still treats many extreme price hikes as politically offensive but not automatically unlawful, especially when exclusionary conduct is hard to prove directly.

Mode 5: Enforcement that arrives after the damage

What it is: Even when regulators eventually act, the process often takes years. Patients do not get those years back.

Examples:

• Vyera’s price spike happened in 2015; major FTC action and meaningful market correction came years later. [confirmed]
• Insulin price escalation ran for years before Congress, the IRA, and political pressure forced partial relief. [confirmed]
• The biggest public hearings often clarified what happened only after the extraction had already become normal. [confirmed]

Missing guardrail: Essential-drug abuses still lack a fast enforcement lane that can freeze obvious gaming before it hardens into the new status quo.

Fallout

• Patients ration drugs, skip refills, or absorb huge out-of-pocket shocks.
• Employers and public purchasers pay into opaque systems they cannot really audit.
• Clinicians spend time fighting formularies and prior-auth churn instead of caring for patients.
• Trust collapses because the public can see that the market is not working, but relief arrives slowly and unevenly.

What good looks like

Drug markets will never be simple, but they should at least be legible and contestable.

What that looks like:

• Real entry: generic and biosimilar competitors can get samples, launch on time, and survive contracting pressure
• Visible money: employers, regulators, and patients can see net prices and middleman cuts instead of guessing
• Cleaner incentives: PBMs and plans do better when total cost goes down, not when list prices climb
• Faster enforcement: obvious abuse triggers action fast enough to matter while patients are still living through it

That is not anti-innovation. It is the minimum for separating real invention from contract-maze rent-seeking.

What would reduce the harm

The short-term job is not to redesign the whole drug market overnight. It is to make essential medicines less hostage-prone while building rules that can hold.

Short term: 0-12 months

• Ban PBM compensation tied directly to list price in public programs and state-regulated markets.
• Require point-of-sale pass-through of rebates or equivalent patient credits where states and large purchasers can do it now.
• Force clearer member-facing price tools that show cash, insured, and expected out-of-pocket pricing in one place.
• Use employer, union, and public-purchaser contracts to demand net-price reporting and anti-spread-pricing terms.

Medium term: 1-3 years

• Expand sample-access protections and fast review when distribution controls appear to block generic entry.
• Require usable reporting of list price, average net price, rebates, and retained fees across the supply chain.
• Tighten scrutiny of pay-for-delay settlements and similar agreements that postpone competition without clinical benefit.
• Build a faster enforcement trigger for extreme price spikes on drugs with no meaningful substitute.

Long term: 3-10 years

• Standardize contracting enough to shrink the space for hidden rebate games.
• Build a more durable biosimilar market with reimbursement and substitution rules that reward actual uptake.
• Create a credible public backstop for essential-drug markets that remain captive and noncompetitive.
• Align innovation rewards with clinical value instead of letting paperwork maneuvers and moat-building drive returns.

Related methods

• primary-documents: FTC action on Vyera, Senate hearings, congressional testimony, FDA records
• official-data: insulin pricing investigations, list-price versus net-price comparisons, relief scope
• independent-analysis: price-spike research, competition analysis, trust and rationing impacts

Back to case studies